Predictors of the Development of Protracted Bacterial Bronchitis Following Presentation to Healthcare for an Acute Respiratory Illness with Cough: Analysis of Three Cohort Studies

Kerry-Ann F. O'Grady 1,*, Juliana Mahon 2, Daniel Arnold 1, Keith Grimwood 3,4, Kerry K. Hall 5, Vikas Goyal 1,6, Julie M. Marchant 1,6, Natalie Phillips 7,8, Jason Acworth 7, Alex King 10, Mark Scott 11 and Anne B. Chang 1,6,12*©

Abstract: We describe the prevalence and risk factors for protracted bacterial bronchitis (PBB) following healthcare presentation for an acute cough illness in children. Data from three studies of the development of chronic cough (CC) in children were combined. PBB was defined as a wet cough of at least 4-weeks duration with no identified specific cause of cough that resolved following 2–4 weeks of appropriate antibiotics. Anterior nasal swabs were tested for 17 viruses and bacteria by polymerase chain reaction. The study included 903 children. Childcare attendance was the most common organism (52.4%) identified in all children (PBB = 72.1%; no PBB = 50.2%). We provide the first data on risks for PBB in children following acute illness and a hypothesis for studies to further investigate the relationship with wheeze-related illnesses. Clinicians and parents/guardians should be aware of these risks and seek early review if a wet cough lasting more than 4-weeks develops the post-acute illness.

Keywords: protracted bacterial bronchitis; children; risk factors
1. Introduction

Since first recognized as a distinct diagnostic entity in 2006 [1], protracted bacterial bronchitis (PBB) is internationally recognized as a significant disease in children associated with a considerable illness burden [2]. PBB is characterized by a wet cough that persists for at least 4-weeks in the absence of specific cough pointers and resolves with a 2- or 4-week course of appropriate antibiotics [3]. PBB, especially when recurrent, is considered part of a spectrum of lung disease, which untreated could progress to bronchiectasis [3,4].

While PBB-specific knowledge has been growing, much of what is now known has been garnered from children referred to specialist pediatric pulmonologists because of chronic cough with scarce community-based data. The European Respiratory Society (ERS) identified a need to better understand the natural history of PBB and collect more data on disease burden at the community level [2]. In particular, there are no data on the risk factors for the development of PBB in children following an acute respiratory illness.

Here, our primary objective was to describe the key epidemiological and clinical predictors of PBB following an acute respiratory illness with cough (ARlwC) in children aged <15-years in urban/regional communities in South-East Queensland, Australia. We hypothesized that risk factors for the development of PBB could be identified. A secondary objective was to describe the prevalence of upper airway viruses and bacteria present at the time of acute illness and at the time of diagnosis of PBB.

2. Materials and Methods

2.1. Design

This was a secondary analysis of data collected in three prospective cohort studies with recruitment undertaken between 11 December 2011 and 6 October 2018. The protocols and primary findings of each study have been published previously [5–10]. All three studies used identical methods and data collection to follow for 4-weeks children aged <15-years with an ARIwC after their presentation to either a primary healthcare clinic (PHC) or an emergency department (ED).

2.2. Setting

Recruitment occurred in three hospital EDs and three PHCs from regional and urban areas in South East Queensland, Australia. The hospitals included a tertiary pediatric hospital in Brisbane, a general hospital located in an outer suburb of Brisbane (Caboolture), and another general hospital in a regional area (Toowoomba). The PHCs included one located in outer Brisbane (Caboolture) and two located in regional areas (Toowoomba/Warwick) approximately 2 h west of Brisbane. The PHCs served predominantly Aboriginal and Torres Strait Islander people.

2.3. Participants

In studies-1 [5] and -2 [9], children were eligible for inclusion if they were aged <15-years and presented with an ARlwC. Exclusion criteria included: (i) known history of chronic lung disease (other than asthma), (ii) primary or secondary immunodeficiency, including immunosuppressive therapy, but excluding short-course (<2-weeks) oral and ongoing maintenance inhaled corticosteroids, in the 30-days prior to presentation, (iii) current or planned participation in another study during the follow-up period for these studies and (iv) insufficient English that would inhibit workbook completion and inability to provide informed consent. Study 3 [7] was a cohort study of children aged <5-years registered with a PHC and followed for 12-months to determine the incidence and outcomes of ARlwC. For this analysis, only Study 3 children who had a cough illness at baseline were included, and subsequent illnesses they had over the following 12-months were excluded.

For this analysis, only children presenting with a cough duration of <14-days at the time of enrolment and who had a known cough outcome at the end of 4-weeks of follow-
up were included. Those who were diagnosed with bronchiectasis or aspiration in the respective studies were excluded.

2.4. Data Collection

Data were collected at baseline from medical records and via parent/guardian interview, at weekly follow-ups (by email, phone and/or in person with parents/carers) for 4-weeks, and at the time of study clinician review if a child had a persistent cough at day-28 following enrolment. Comprehensive epidemiological and clinical data, including cough history, were collected at each time point. Diagnoses at discharge were those recorded by the attending clinician in the ED or PHC and were not standardized for the study. Three attempts were made to contact parents/carers. If there was no contact for two consecutive weeks, the child was classified as lost to follow-up. Anterior nasal swabs (included swabbing of both nares) were collected at baseline and at the time of physician review.

Persistent cough was defined as the presence of daily cough over the 4-week period with no more than a 3-day/night break in cough. Children with a break in cough at any time point were classified as cough resolved, and children for whom cough status was unknown at any time point were classified as unknown cough status unless at a previous timepoint the cough had resolved.

On day-28, children with persistent cough were invited for clinical review by a pediatric respiratory physician within 2-weeks of this timepoint. An exception was for some children in study 2 [10], where those with persistent cough were randomized to either an intervention arm and reviewed within the next 2-weeks or to a control arm and reviewed after day-56 if their cough persisted [10]. Children were reviewed in accordance with cough management guidelines [11,12] and in Study 2, according to a cough management algorithm [13].

2.5. Primary Outcome

The primary outcome was a diagnosis of PBB by study clinicians at review. For a provisional diagnosis of PBB, the child had to have at least 4-weeks of wet cough in the absence of specific cough pointers. The 4-weeks of persistent wet cough were confirmed by review of cough type recorded at weekly contacts up to day-28 and at the time of clinician review and the clinician’s history taking with the child’s parent/carer. Children with a provisional diagnosis of PBB were subsequently treated with at least 2-weeks of antibiotics (usually amoxicillin-clavulanate unless this was contraindicated because of prior hypersensitivity). The children were first prescribed a 2-week course and, if the cough did not resolve, a further 2 weeks was dispensed. The diagnosis was not confirmed until the cough had resolved following either 2- or 4-weeks of appropriate antibiotics, in accordance with the definition of PBB [3].

2.6. Laboratory Methods

All nasal swabs were processed using identical, previously published methods at the Queensland Paediatric Infectious Diseases Laboratory [5,9]. In study 2, the collection of nasal specimens was ceased approximately halfway through the study for financial reasons. Multiplex polymerase chain reaction (PCR) assays were used to detect *Streptococcus pneumoniae*, *Haemophilus influenzae* (capsulated and unencapsulated), *Moraxella catarrhalis*, *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, *Bordetella pertussis*, human rhinovirus, adenovirus, enterovirus, influenza viruses (A and B), respiratory syncytial virus (A and B), parainfluenza virus (1, 2 and 3), human metapneumovirus, human bocavirus-1, human coronaviruses (HUK1, OC43, NL63, and 229E), and human polyomaviruses KI and WU.

2.7. Statistical Methods

The baseline characteristics of children were described with means or medians for continuous data, and proportions for categorical data and groups were compared with the Student t-test, the Kruskal-Wallis test, or chi² tests, respectively. Backward stepwise logistic
regression with robust standard errors to adjust for clustering by study site was undertaken to identify independent predictors of PBB. Variables with a \( p \)-value < 0.10 in univariate analyses, and those considered potentially clinically relevant, were included in the models with both crude and adjusted relative risks (aRR) presented with their 95% confidence intervals (CI). Interaction terms were included in regression models where indicated. Age, sex, and First Nations status were retained as adjustment factors in all models irrespective of statistical significance.

3. Results

Between 11 December 2011 and 6 October 2018, 1458 participants were enrolled across the three studies, and 910 (62.1%) children were included initially in this analysis (Figure 1). The mean age was 3.2-years (standard deviation [SD] 3.1), 59.4% were male, and 16.3% identified as Australian First Nations. The most common diagnoses at baseline for the whole cohort were upper respiratory tract infections (30.9%) and asthma/reactive airways disease (25.6%); 27.3% of children had received antibiotics in the 7-days prior to presentation or at the time of presentation.

Persistent cough at day-28 following presentation was present in 254 children (27.9%, 95% CI 25.0–30.8), and 162 (63.7%) of those children completed clinician review. Reasons for not attending review were: lost to follow-up after day-28 \( (n = 32) \), parent decision not to attend \( (n = 26) \), cough resolved by time of appointment \( (n = 25) \) and other reasons \( (n = 9) \). Among those who completed their review, five were diagnosed with bronchiectasis and two with aspiration. They were subsequently excluded leaving 903 children for the final analysis (Figure 1). Children with a persistent cough for whom clinician review was not completed were classified as not having PBB. There were no differences in age, sex,
Aboriginal and/or Torres Strait Islander status, and cough severity at day-28 between children who did and did not present for review.

Eighty-six children (9.5%) had a confirmed diagnosis of PBB. The median age of children with PBB was 1.0 year (interquartile range (IQR), 0.7–2.0), 59.1% were male, and 20.9% identified as Aboriginal and/or Torres Strait Islander. The baseline characteristics of children with and without PBB are presented in Table 1.

**Table 1.** Baseline characteristics of children presenting with cough duration <14-days by a diagnosis of PBB following day-28 *

| Variable                        | PBB Diagnosis | Total | p-Value |
|---------------------------------|---------------|-------|---------|
|                                 | No            | Yes   |         |
| Study                           | n = 817 (90.5%) | n = 86 (9.5%) | n = 903 (100%) |
| ED Cough                        | 549 (67.2)    | 53 (61.6) | 602 (66.7) | 0.001 |
| RICCI Kids                      | 232 (28.4)    | 21 (24.4) | 253 (28.0) |
| TLSIMM Kids                     | 36 (4.4)      | 12 (14.0) | 48 (5.3) |
| Age group (years)               |               |       |         |
| <1                              | 149 (18.2)    | 32 (37.2) | 181 (20.0) | <0.001 |
| 1–<2                            | 208 (25.5)    | 31 (36.1) | 239 (26.5) |
| 2–<5                            | 248 (30.3)    | 20 (23.3) | 268 (29.7) |
| ≥5                              | 212 (26.0)    | 3 (3.5)  | 215 (23.8) |
| Sex                             |               |       |         |
| Male                            | 482 (59.0)    | 52 (60.5) | 534 (59.1) | 0.792 |
| Female                          | 335 (41.0)    | 34 (39.5) | 369 (40.9) |
| Indigenous status of the child  |               |       |         |
| Other                           | 689 (84.3)    | 68 (79.1) | 757 (83.8) | 0.207 |
| First Nations Australian        | 128 (15.7)    | 18 (20.9) | 146 (16.1) |
| Birthweight                     |               |       |         |
| <2500 g                         | 72 (8.8)      | 6 (7.0)  | 78 (8.6)  | 0.564 |
| ≥2500 g                         | 745 (91.2)    | 80 (93.0) | 825 (91.4) |
| Gestational age                 |               |       |         |
| <37-weeks                       | 82 (10.0)     | 9 (10.5)  | 91 (10.1)  | 0.900 |
| ≥37-weeks                       | 735 (90.0)    | 77 (89.5) | 812 (89.9) |
| Season of enrolment             |               |       |         |
| Summer                          | 155 (19.0)    | 15 (17.4) | 170 (18.8) | 0.236 |
| Autumn                          | 271 (33.2)    | 22 (25.6) | 293 (32.4) |
| Winter                          | 273 (33.4)    | 38 (44.2) | 311 (34.4) |
| Spring                          | 118 (14.4)    | 11 (12.8) | 129 (14.3) |
| Attends childcare               |               |       |         |
| Yes                             | 368 (45.0)    | 53 (61.6) | 421 (46.6) | 0.004 |
| No                              | 370 (45.3)    | 31 (36.1) | 401 (44.4) |
| Not applicable (≥6-years of age) | 79 (9.7)     | 2 (2.3)   | 81 (9.0)  |
Table 1. Cont.

| Variable                                      | PBB Diagnosis | Total |  p-Value 1 |
|-----------------------------------------------|---------------|-------|------------|
|                                               | No            | Yes   | n = 903 (100%) |
| Exposed to indoor tobacco smoke               |               |       |             |
| Yes                                           | 114 (13.9)    | 11 (12.8) | 125 (13.8) | 0.766 |
| No                                            | 703 (86.1)    | 75 (87.2) | 778 (86.2) |
| Number of other children in the house         |               |       |             |
| 0                                              | 230 (28.1)    | 36 (41.8) | 266 (29.5) | 0.027 |
| 1                                              | 347 (42.5)    | 28 (32.6) | 375 (41.5) |
| ≥2                                             | 240 (29.4)    | 22 (25.6) | 262 (29.0) |
| Pets at home                                  |               |       |             |
| Yes                                            | 429 (52.5)    | 52 (60.5) | 481 (53.2) | 0.160 |
| No                                             | 388 (47.5)    | 34 (39.5) | 422 (46.7) |
| Previous history of cough lasting >4-weeks     |               |       |             |
| Yes                                            | 160 (19.6)    | 29 (33.7) | 189 (20.9) | 0.002 |
| No                                             | 657 (80.4)    | 57 (66.3) | 714 (79.1) |
| History of wheeze (parent-reported)           |               |       |             |
| Yes                                            | 447 (54.7)    | 49 (57.0) | 496 (54.9) | 0.688 |
| No                                             | 370 (45.3)    | 37 (43.0) | 407 (45.1) |
| History of eczema                              |               |       |             |
| Yes                                            | 207 (25.3)    | 13 (15.1) | 220 (24.4) | 0.036 |
| No                                             | 610 (74.7)    | 73 (84.9) | 683 (75.6) |
| Asthma diagnosis in past 12-months            |               |       |             |
| Yes                                            | 160 (19.6)    | 4 (4.6) | 164 (18.2) | 0.001 |
| No                                             | 657 (80.4)    | 82 (95.4) | 739 (81.8) |
| Cough type at presentation                     |               |       |             |
| Dry                                            | 286 (35.0)    | 19 (22.1) | 305 (33.8) | 0.009 |
| Wet                                            | 313 (38.3)    | 32 (37.2) | 345 (38.2) |
| Variable                                       | 218 (26.7)    | 35 (40.7) | 253 (28.0) |
| Steroids (inhaled or oral) for current illness|               |       |             |
| Yes                                            | 277 (33.9)    | 17 (19.8) | 294 (32.6) | 0.008 |
| No                                             | 540 (66.1)    | 69 (80.2) | 609 (67.4) |
| Antibiotics for current illness                |               |       |             |
| Yes                                            | 225 (27.5)    | 22 (25.6) | 247 (27.3) | 0.698 |
| No                                             | 592 (72.5)    | 64 (74.4) | 656 (72.7) |
Table 1. Cont.

| Variable | PBB Diagnosis | Total | p-Value 1 |
|----------|---------------|-------|-----------|
|          | No n = 817 (90.5%) | Yes n = 86 (9.5%) | n = 903 (100%) |
| Diagnosis at discharge | | | |
| Upper respiratory tract infection 6 | 242 (29.6) | 37(43.0) | 279 (30.9) | Not done |
| Asthma/reactive airways disease | 223 (27.3) | 8 (9.3) | 231 (25.6) |
| Croup | 81 (9.9) | 9 (10.5) | 90 (10.0) |
| Bronchiolitis | 72 (8.8) | 3 (3.5) | 75 (8.3) |
| Pneumonia/lower respiratory tract infection | 52 (6.3) | 7 (8.3) | 59 (6.5) |
| Bronchitis | 4 (0.5) | 1 (1.2) | 5 (0.5) |
| Other 4 | 88 (10.8) | 8 (9.3) | 96 (10.6) |
| Not documented | 55 (6.7) | 13 (15.1) | 68 (7.5) |

Hospitalized for current illness

| | Yes | No |
|---------------------------------|------|-----|
| 278 (34.0) | 309 (66.0) | 587 (65.0) |

Abbreviations: ED Cough—Emergency Department Cough Study; RICCI Kids—Researching Intervention in Chronic Cough in Kids; TLSIM Kids—Tooth and Lung Sickness in Murri Kids; PBB—protracted bacterial bronchitis. 4 p-value—this is either the comparison of proportions between children with and without PBB or when there are multiple categories; it is the overall p-value for this comparison across multiple strata. 6 Children who did not have persistent cough at day-28 and amongst those who did have persistent cough at day-28 but did not present for review or had a diagnosis other than PBB were classified as not having PBB. § Steroid use in 7-days prior to presentation or given/prescribed at presentation. §§ Antibiotic use in 7-days prior to presentation or given/prescribed at presentation. £ Upper respiratory tract infection includes cases with a diagnosis of unspecified viral illness/infection. 4 Other includes 10 cases of influenza/ influenza-like illness and 4 cases of pertussis, none of whom developed PBB.

Table 2 presents the independent predictors of PBB identified in regression models. Childcare attendance (aRR 2.32, 95% CI 1.48–3.63), a prior history of chronic cough (aRR 2.63, 95% CI 1.72–4.01), age <2-years (<12-months: aRR 4.31, 95% CI 1.42–13.1; 12-<24-months: aRR 2.00, 95% CI 1.35–2.96) and parent-reported wheeze in the past 12-months (aRR 1.89, 95% CI 1.61–2.23) were associated with an increased risk of PBB. Baseline reports of a diagnosis of asthma in the previous 12-months (aRR 0.28, 95% CI 0.24–0.33) were associated with a decreased risk. Among the baseline clinical diagnoses, asthma/reactive airways disease (aRR 0.32, 95% CI 0.15–0.67) and bronchiolitis (aRR 0.14, 95% CI 0.06–0.31) were associated with a decreased risk of PBB. Eight of 231 children with asthma/RAD at baseline were diagnosed with PBB.

Baseline nasal swabs were available for PCR testing for 687/903 (76.1%) children, 68/86 (79.1%) children diagnosed with PBB, and 619/817 (75.8%) without PBB (Table 3). Overall, both viruses and bacteria were detected in 48.8% of swabs, 55.9% in children with PBB, and 48.0% in those without this diagnosis (p = 0.216). Co-detection of ≥2 viruses and/or bacteria occurred in 68.2% of swabs, 79.3% in children with PBB and 67.1% of children without PBB (p = 0.040). The most common bacterium identified at baseline was M. catarrhalis (52.4%), with a higher proportion detected in children subsequently diagnosed with PBB (72.1%) compared to 50.2% in other children (p < 0.001). Rhinovirus was the most common virus identified (27.9%), with no differences between children with and without PBB.
Table 2. Predictors for protracted bacterial bronchitis following an acute respiratory illness with cough in children aged <15-years, (n = 903).

| Variable | PBB/n | Crude RR | 95% CI | Adjusted RR | 95% CI | p-Value |
|----------|-------|----------|--------|-------------|--------|---------|
| Female sex | 34/369 | 1.03 | 0.68–1.56 | 0.93 | 0.54–1.58 | 0.778 |
| Australian First Nations child | 18/146 | 1.42 | 0.87–2.31 | 1.05 | 0.82–1.35 | 0.689 |
| Age group (months) | | | | | | |
| <12-months | 32/181 | 4.30 | 2.41–7.66 | 4.31 | 1.42–13.1 | 0.010 |
| 12–<24-months | 31/239 | 3.10 | 1.75–5.30 | 2.00 | 1.35–2.96 | 0.001 |
| >24-months | 23/483 | Ref | Ref | Ref | Ref | Ref |
| Childcare attendance | 53/421 | 1.86 | 1.22–2.83 | 2.32 | 1.48–3.63 | <0.001 |
| Prior history of cough lasting >4-weeks | 29/189 | 1.79 | 1.17–2.76 | 2.63 | 1.72–4.01 | <0.001 |
| Parent reported wheeze past 12-months | 49/496 | 1.32 | 0.80–2.20 | 1.73 | 1.17–2.58 | 0.007 |
| Diagnosis of asthma in past 12-months | 4/164 | 1.25 | 0.67–2.31 | 1.05 | 0.82–1.35 | 0.689 |
| Diagnosis of asthma and parent reported wheeze past 12-months | 2/126 | 0.15 | 0.04–0.59 | 0.35 | 0.16–0.75 | 0.007 |
| History of eczema | 13/220 | 0.55 | 0.31–0.98 | 0.73 | 0.48–1.11 | 0.144 |

Clinical diagnosis on the day of enrolment

| Upper respiratory tract infection £ | 37/279 | Ref | 0.146 |
| Asthma/RAD | 8/231 | 0.23 | 0.11–0.51 | 0.32 | 0.15–0.67 | 0.002 |
| Bronchiolitis | 3/75 | 0.27 | 0.08–0.91 | 0.14 | 0.06–0.31 | <0.001 |
| Bronchitis | 1/5 | 1.64 | 0.18–15.0 | 3.24 | 0.14–73.77 | 0.461 |
| Croup | 9/90 | 0.73 | 0.34–1.57 | 0.73 | 0.38–1.39 | 0.343 |
| Pneumonia, LRTI | 7/59 | 0.88 | 0.37–2.08 | 1.05 | 0.74–1.68 | 0.879 |
| Other | 8/96 | 0.59 | 0.27–1.32 | 0.84 | 0.71–0.99 | 0.036 |
| Not documented | 13/68 | 1.54 | 0.77–3.10 | 1.67 | 0.93–3.01 | 0.083 |

Abbreviations: CI—confidence interval; LRTI—lower respiratory tract infection; PBB—protracted bacterial bronchitis; RAD—reactive airways disease; RR—relative risk. Models incorporated robust standard errors to account for clustering by study. Interaction term for asthma x wheeze. Upper respiratory tract infection includes cases with a diagnosis of unspecified viral illness/infection. Other includes 10 cases of influenza/influenza-like illness and 4 cases of pertussis, none of whom developed PBB. Not documented includes children who were given a diagnosis of “Cough”.

Table 3. Baseline microbiology (n = 687 children).

| Organism detected | No | Yes | Total | p-Value * |
|-------------------|----|-----|-------|---------|
| None | 84 (13.6) | 8 (11.8) | 92 (13.4) | 0.146 |
| Bacteria only | 166 (26.8) | 20 (29.4) | 206 (28.0) | |
| Virus only | 72 (11.6) | 2 (2.9) | 74 (10.8) | |
| Both virus and bacteria | 297 (48.0) | 38 (55.9) | 335 (48.8) | |

| Total bacteria detected | No | Yes | Total | p-Value * |
|-------------------------|----|-----|-------|---------|
| 0 | 156 (25.2) | 10 (14.7) | 166 (24.2) | |
| 1 | 189 (30.5) | 20 (29.4) | 209 (30.4) | 0.141 |
| 2 | 169 (27.3) | 25 (36.8) | 194 (28.2) | |
| 3 | 94 (15.2) | 10 (14.7) | 104 (15.1) | |
| 4 | 10 (1.6) | 3 (4.4) | 13 (1.9) | |
| 5 | 1 (0.2) | 0 | 1 (0.1) | |

| Total viruses detected | No | Yes | Total | p-Value * |
|------------------------|----|-----|-------|---------|
| 0 | 151 (24.4) | 12 (17.6) | 163 (23.7) | 0.169 |
| 1 | 241 (38.9) | 23 (33.8) | 264 (38.4) | |
| 2 | 181 (29.2) | 24 (35.3) | 205 (29.8) | |
| 3 | 40 (6.5) | 7 (10.3) | 47 (6.8) | |
| 4 | 6 (1.0) | 2 (2.9) | 8 (1.2) | |

| Total viruses and/or bacteria detected | No | Yes | Total | p-Value * |
|----------------------------------------|----|-----|-------|---------|
| 0 | 81 (13.1) | 8 (11.8) | 89 (12.9) | |
| 1 | 123 (19.9) | 6 (8.8) | 129 (18.8) | |
| 2 | 106 (17.1) | 9 (13.2) | 115 (16.7) | |
| 3 | 104 (16.8) | 12 (17.6) | 116 (16.9) | |
| 4 | 105 (17.0) | 23 (33.8) | 128 (18.6) | |
| 5+ | 100 (16.2) | 10 (14.7) | 110 (16.0) | |
Table 3. Cont.

|                      | PBB                                      |                  |                  |                  | p-Value * |
|----------------------|------------------------------------------|------------------|------------------|------------------|-----------|
|                      | No n = 619 (%)                           | Yes n = 68 (%)   | Total n = 687 (%)|                  |           |
| Specific bacteria detected |                                          |                  |                  |                  |           |
| *Streptococcus pneumonia* | 307 (49.6)                              | 32 (47.1)        | 339 (49.3)       | 0.691            |           |
| *Haemophilus influenzae* | 207 (33.4)                              | 28 (41.2)        | 235 (34.2)       | 0.198            |           |
| *Moraxella catarrhalis* | 311 (50.2)                              | 49 (72.1)        | 360 (52.4)       | <0.001           |           |
| Bordetella pertussis  | 5 (0.8)                                 | 0                | 5 (0.7)          | -                |           |
| *Mycoplasma pneumoniae* | 8 (1.3)                                 | 0                | 8 (1.2)          | -                |           |
| Chlamydia pneumoniae  | 3 (0.5)                                 | 0                | 3 (0.4)          | -                |           |
| Specific viruses detected |                                        |                  |                  |                  |           |
| Rhinovirus            | 172 (27.8)                              | 20 (29.4)        | 192 (27.9)       | 0.735            |           |
| Adenovirus            | 29 (4.7)                                | 3 (4.4)          | 32 (4.6)         | 0.934            |           |
| Respiratory syncytial virus (A & B) | 104 (16.8) | 7 (10.3)       | 111 (16.1)       | 0.087            |           |
| Parainfluenza (1, 2 & 3) | 35 (5.6)                              | 6 (8.8)          | 41 (6.0)         | 0.283            |           |
| Influenza (A & B)     | 22 (3.5)                                | 2 (2.9)          | 24 (3.5)         | 1.000            |           |
| Enterovirus           | 24 (3.9)                                | 1 (1.5)          | 25 (3.6)         | 0.499            |           |
| Human bocavirus-1     | 16 (2.5)                                | 2 (2.9)          | 18 (2.6)         | 0.693            |           |
| Human metapneumovirus | 14 (2.0)                                | 2 (2.9)          | 16 (2.3)         | 0.664            |           |
| Human coronavirus HUK1, OC43, NL63 & 229E | 18 (2.9) | 3 (3.7)        | 21 (3.1)         | 0.454            |           |
| Human polyomavirus: KI & WU | 6 (1.0)                              | 4 (5.9)          | 10 (1.5)         | 0.012            |           |

* p-value—for comparison of proportions between children with and without PBB. Where multiple categories exist, the p-value is for the comparison across multiple strata.

Specimens were available at both baseline and specialist review for 60 (71.4%) children with PBB (Table 4); *M. catarrhalis* was the most common organism detected at both timepoints.

Table 4. Nasal microbiology in children with PBB at baseline, at time of specialist review, and who were positive at both time points (N = 60 children with specimens at both time points).

| Organism detected | Baseline | Specialist Review | Both Timepoints in the Same Children |
|-------------------|----------|-------------------|--------------------------------------|
| None              | 6 (10.0) | 8 (13.3)          | 2 (3.3)                              |
| Bacteria only     | 16 (26.7)| 25 (41.7)         | 7 (11.7)                             |
| Virus only        | 2 (3.3)  | 3 (5.0)           | 0                                    |
| Both virus and bacteria | 36 (60.0) | 24 (40.0)     | 14 (23.3)                            |
| Specific bacteria detected |                                      |                                        |                                        |
| *Streptococcus pneumoniae* | 28 (46.7) | 38 (63.3)         | 22 (36.7)                            |
| *Haemophilus influenzae* | 24 (40.0)| 24 (40.0)         | 14 (23.3)                            |
| *Moraxella catarrhalis* | 44 (73.0) | 43 (71.7)         | 33 (55.0)                            |
| Bordetella pertussis | 0        | 0                 | 0                                    |
| *Mycoplasma pneumoniae* | 0        | 0                 | 0                                    |
| Chlamydia pneumoniae | 0        | 0                 | 0                                    |
| Specific viruses detected |                                      |                                        |                                        |
| Rhinovirus        | 19 (31.7)| 12 (20.0)         | 2 (3.3)                              |
| Adenovirus        | 3 (5.0)  | 6 (10.0)          | 0                                    |
| Respiratory syncytial virus (A & B) | 7 (11.7) | 1 (1.7)         | 0                                    |
| Parainfluenza (1, 2 & 3) | 6 (10.0) | 2 (3.3)          | 1 (1.7)                              |
Table 4. Cont.

|                          | Baseline | Specialist Review | Both Timepoints in the Same Children |
|--------------------------|----------|-------------------|--------------------------------------|
| Influenza (A & B)        | 2 (3.3)  | 1 (1.7)           | 0                                    |
| Enterovirus              | 1 (1.7)  | 5 (8.3)           | 0                                    |
| Human bocavirus-1        | 2 (3.3)  | 2 (3.3)           | 0                                    |
| Human metapneumovirus    | 0        | 0                 | 0                                    |
| Human coronavirus HKU1, OC43, NL63 & 229E | 2 (3.3)  | 5 (8.3)           | 0                                    |
| Human polyomavirus—KI & WU | 3 (5.0)  | 5 (8.3)           | 1 (1.7)                              |

Note: Mean number of days between baseline swab and specialist swab = 45 days (95% CI 41.8–48.5).

4. Discussion

Our prospective study involving 903 children recruited from the community who presented with ARIwC determined the proportion and characteristics of, and risk factors for, children who subsequently developed PBB diagnosed by pediatric pulmonologists in accordance with cough management guidelines [11–13]. Overall, 9.3% of all children were diagnosed with PBB. Childcare attendance, age <2-years, parent-reported wheeze in the past 12-months and a prior history of chronic cough were associated with an increased risk of PBB, whereas a prior diagnosis of asthma and being diagnosed at the time of acute presentation with asthma/reactive airways disease or bronchiolitis were associated with a decreased risk. Upper airway detection of *M. catarrhalis* was more common in children with PBB than those without this diagnosis.

Studies examining risk factors for chronic cough generally in children post-ARIwC are limited. To our knowledge, this is the first study to examine risk factors for the development of PBB post-ARIwC in children. Furthermore, it is important as it fulfills a clinical-research gap identified by the ERS PBB task force [2]. PBB was the most common diagnosis amongst all children reviewed by clinicians following identification of chronic cough post-ARIwC in the three primary studies on which this analysis was based [6,8,10]. This is consistent with Australian data, where PBB is also amongst the most common diagnoses in children with established chronic cough referred to tertiary pediatric respiratory clinics, particularly in younger children [1,13–18]. An advantage of our study is most studies of chronic cough in children are based on those referred to specialist centers, often after long durations of cough [1,13–18]. Identifying, diagnosing, and treating chronic cough and PBB early in the illness improves clinical outcomes [10]. Our study enrolled children early in an ARIwC, and 22% of children diagnosed with PBB had a dry cough at baseline, suggesting an early transition from dry to wet cough that persisted. The rapid assessment and treatment of these children are important for preventing adverse sequelae and improving the quality of life of children and their carers. Additional strengths of our study are that all three included studies employed identical methods to determine cough persistence in children following acute presentation to healthcare and the inclusion of both PHC and ED sites. Furthermore, pediatric pulmonologists established PBB diagnosis following evidence-based guidelines [11,12] and algorithms [13].

Similar to the primary studies on the development of chronic cough [6,8,19], our study found that childcare attendance, young age, and a prior history of chronic cough were risk factors for PBB development. Amongst children in childcare, those who continued to attend while unwell with a cough illness were 13 times (adjusted odds ratio (OR) = 12.9, 95% CI 3.9, 43.3) more likely to develop chronic cough than those who remained absent [19]. Moreover, when children with chronic wet cough undergoing bronchoscopy were compared with children undergoing bronchoscopy for indications other than a cough, those with PBB were more likely to have attended childcare (OR 8.4, 95% CI 2.3–30.5), although this effect was no longer significant on multivariable analyses [20]. We also found that parent-reported wheeze in the past 12-months increased the risk of having PBB. This is not surprising as previously reported wheeze by parents is not uncommonly described in PBB cohort studies [20], although frequently absent on auscultation by a doctor [21].
Furthermore, the reliability of parent-reported wheeze varies, and disagreement with physicians and objective tests is common, particularly as an indicator for the diagnosis of asthma [22,23]. However, despite the very small numbers, when considering interaction effects with parent-reported wheeze and a parent-reported diagnosis of asthma in the past 12-months, a protective effect was observed.

While asthma can coexist with PBB and misdiagnosis of asthma in young children is common [22,24], the finding in our study that children with diagnoses of wheeze-related illnesses (asthma, reactive airways disease, and bronchiolitis) at the time of acute presentation were less likely to develop PBB contradicts the parent-reported history of wheeze as a risk factor.

Our finding of a decreased risk of PBB in children with asthma and bronchiolitis has not been reported previously. As our study did not involve mechanistic components, reasons for this finding can only be speculated. Nevertheless, a systematic review of studies on a chronic cough that assessed time-to-cough resolution found that when asthma is treated effectively, the cough resolves within 2–4 weeks [25]. Indeed, the first study that reported on adults who presented with cough found that in all seven adults (who also had airway obstruction evidenced on spirometry), their cough resolved within a week of treatment [26]. Unsurprisingly, evidence-based cough guidelines recommend that if asthma medications are used to treat cough, a trial period of 2–4 weeks suffices and should be ceased if not effective [27]. Moreover, children with acute asthma have a faster resolution of cough and subjective acute respiratory illness symptoms (measured using Canadian acute respiratory illness and flu scale [CARIFS]) than children with PBB [28].

Although children with asthma and PBB have similar CARIFS scores at baseline/day-1 (which were both significantly higher than controls with an acute respiratory illness), by day-14 CARIFS scores in the PBB group (median = 19.6, IQR = 25.8) were significantly higher than in both controls (median = 4.1, IQR 5.3) and those with asthma (median = 4.1, IQR 4) [28]. Reasons for this are unknown, but possible mechanisms include dysfunctional host responses [29,30] and lower airway bacteria and biofilms [31] in some children who develop a PBB phenotype.

Another reason is that although the doctors who evaluated these children for chronic cough were specialists and followed an evidenced-based algorithm, it is possible that they were less likely to diagnose PBB when children had asthma/RAD or bronchiolitis. However, this is highly unlikely as eight children of 231 with asthma/RAD at baseline were still diagnosed with PBB.

Caution is required when interpreting the observed associations with clinical diagnoses as, unlike the assessment for children with chronic cough, there was no systematic approach to the diagnosis of children at baseline. Moreover, there was a high proportion for whom no diagnosis was reported, including giving a diagnosis of “cough.” The problems with consistent and accurate diagnoses of viral respiratory illnesses, particularly with wheeze, are considered a result of inadequate understanding of underlying inflammatory processes and different clinical presentations across age groups [32]. Additionally, the diagnosis of asthma was not validated in our cohort, although there is difficulty in confirming asthma in children aged <5-years. However, given the importance of PBB, the potential for wheeze-associated illnesses to inform the underlying pathophysiological processes associated with the natural history of PBB warrants further investigation.

While upper airway specimens are poor indicators of lower airway bacterial infection identified by culture of bronchoalveolar lavage (BAL) specimens in children with chronic wet cough [33,34], we described upper airway microbiology at the time of ARIwC between those who did and did not develop PBB. Viral-bacterial co-detection was common in all children, and there were few differences between children with and without PBB other than for *M. catarrhalis* and human polyomaviruses. Given the very small numbers (10 positive children only), the interpretation of the human polyomavirus finding is limited. Baseline upper airway detection of *M. catarrhalis* in our study was almost 50% higher in children who were subsequently diagnosed with PBB than in those who were not, a
difference not observed with *S. pneumoniae* or *H. influenzae*. Furthermore, *M. catarrhalis* was detected at both baseline and physician review in 55% of children with PBB compared with 37% for *S. pneumoniae* and 23% for *H. influenzae*. *M. catarrhalis* colonization is common in healthy young children with prevalence varying by age and geography [35]. It is one of the three common causes of otitis media in children [36], exacerbations of COPD in adults [37,38], and is often within the top three bacteria detected in BAL specimens collected from children with PBB [39]. In previously published analyses of upper-airway specimens from Study 1 [40], children who were nasal swab positive for *M. catarrhalis* at baseline were 2.1 times (95% CI 1.3–3.1) more likely to have cough persistence at day-28 compared with those who were swab negative in multinomial regression models. *M. catarrhalis* was the only microbial difference between children with and without cough persistence; however, this may partly result from inadequate numbers for meaningful analysis of other organisms. There are limited studies on the role of *M. catarrhalis* in the natural history of chronic cough in children, and future studies should include serial testing at more regular intervals to further explore our findings.

Despite the novelty of our study, it has major limitations. Firstly, in addition to the above points relating to diagnoses at baseline and the difficulty in diagnosing young children with asthma, we included children diagnosed as ‘reactive airway disease’ with asthma [41]. We did this as we have found that the term ‘reactive airway disease’ is increasingly used by non-pulmonologists, including in children who have clear-cut asthma. Secondly, a relatively high proportion of children were excluded from being lost to follow-up, both prior to day-28 and at clinician review. However, analyses in each of the three primary studies suggested attrition occurred amongst children with shorter illness duration at baseline and, given the incentive of expedited specialist review of children with chronic cough and the burden of chronic cough and PBB [42–44], it is highly likely that these children did not have PBB (thus diluting our findings). Thirdly, our cohorts were heterogeneous. However, while this may be a limitation, it may also be a strength as PBB can coexist with wheeze and asthma phenotypes [45], and it represents a true-life scenario. Furthermore, as described above, caution is required with the baseline clinical diagnoses. However, the consistency of the association between illnesses characterized by wheeze and a decreased risk of PBB supports the need for further studies to investigate this relationship in detail.

Our study provides the first data on risk factors for PBB in children following ARIwC. It provides a hypothesis for studies to further investigate the relationship between wheeze-related illnesses and PBB in young children, as this may provide more understanding of the natural history and underlying pathophysiology of PBB. Identifying intervention points to prevent progression and, possibly, recurrent episodes associated with the development of bronchiectasis [45] would advance efforts to reduce the disease burden. Clinicians should be aware of the potential for PBB following ARIwC, particularly in young children with prior history of chronic cough and those in childcare. Parents/carers should be counseled to seek a timely medical review if a wet cough of >4-weeks occurs.

**Author Contributions:** Conceptualization, K.-A.F.O., J.M., A.B.C., K.K.H. and K.G.; methodology, K.-A.F.O., K.G., K.K.H. and A.B.C.; software, D.A.; formal analysis, K.-A.F.O.; investigation, K.-A.F.O., J.M., D.A., V.G., J.M.M., N.P., J.A., A.K., M.S. and A.B.C.; resources, K.-A.F.O.; data curation, K.-A.F.O., J.M. and D.A.; writing—original draft preparation, K.-A.F.O. and A.B.C.; writing—review and editing, K.-A.F.O., J.M., D.A., K.G., K.K.H., V.G., J.M.M., N.P., J.A., A.K., M.S., A.B.C. and J.M.M.; supervision, K.-A.F.O., N.P., J.A., A.K. and M.S.; project administration, K.-A.F.O.; funding acquisition, K.-A.F.O., A.B.C. and K.G. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was funded by the Australian National Health and Medical Research Council (GN1080298, 1045157, 1040830), a Queensland Government Smart Futures Fellowship, Project and Program Grants from the Queensland Children’s Medical Research Institute, The University of Queensland, and Queensland University of Technology Aboriginal and Torres Strait Islander Health Research Start-up Grants and a Queensland University of Technology Vacation Research Experience Scheme Scholarship.
Institutional Review Board Statement: The three studies were approved by: the Human Research Ethics Committees of The University of Queensland (2012000700, 2012001395), Queensland University of Technology (140000057, 1300000741, 1500000132), and Children’s Health Queensland (HREC/11/QRCH/83, HREC/12/QRCH/169, HREC/15/QRCH/15) as per the published protocols [5,7,9].

Informed Consent Statement: Written informed consent was obtained from all parents/guardians of children involved in the three studies.

Data Availability Statement: The data from this study can be made available following a written request to the authors; data on Aboriginal and Torres Strait Islander children may be subject to some restrictions.

Acknowledgments: The authors would like to thank the staff of the participating health services for their support of this study. We also thank the staff of the Respiratory infection Outreach and Research Team and the Cough, Asthma and Airways Research Group at the Queensland University of Technology for their commitment to the three studies. We acknowledge the Traditional Owners of the lands on which this research took place and pay our respect to Elders past, present, and emerging.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Marchant, J.M.; Masters, I.B.; Taylor, S.M.; Cox, N.C.; Seymour, G.J.; Chang, A.B. Evaluation and outcome of young children with chronic cough. *Chest* 2006, 129, 1132–1141. [CrossRef] [PubMed]
2. Kantar, A.; Chang, A.B.; Shields, M.D.; Marchant, J.M.; Grimwood, K.; Grigg, J.; Priftis, K.N.; Cutrera, R.; Midulla, F.; Brand, P.P.; et al. ERS statement on protracted bacterial bronchitis in children. *Eur. Respir. J.* 2017, 50, 1602139. [CrossRef] [PubMed]
3. Chang, A.B.; Redding, G.J.; Everard, M.L. Chronic wet cough: Protracted bronchitis, chronic suppurative lung disease and bronchiectasis. *Pediatr. Pulmonol.* 2008, 43, 519–531. [CrossRef] [PubMed]
4. Chang, A.B.; Bush, A.; Grimwood, K. Bronchiectasis in children: Diagnosis and treatment. *Lancet* 2018, 392, 866–879. [CrossRef]
5. Drescher, B.J.; Chang, A.B.; Phillips, N.; Acworth, J.; Marchant, J.; Sloots, T.P.; David, M.; O’Grady, K.A. The development of chronic cough in children following presentation to a tertiary paediatric emergency department with acute respiratory illness: Study protocol for a prospective cohort study. *BMC Pediatr.* 2013, 13, 125. [CrossRef]
6. O’Grady, K.F.; Drescher, B.J.; Goyal, V.; Phillips, N.; Acworth, J.; Marchant, J.M.; Chang, A.B. Chronic cough postacute respiratory illness in children: A cohort study. *Arch. Dis. Child.* 2017, 102, 1044–1048. [CrossRef]
7. Hall, K.K.; Chang, A.B.; Sloots, T.P.; Anderson, J.; Kemp, A.; Hammill, J.; Otim, M.; O’Grady, K.A. The respiratory health of urban indigenous children aged less than 5 years: Study protocol for a prospective cohort study. *BMC Pediatr.* 2015, 15, 56. [CrossRef] [PubMed]
8. Hall, K.K.; Chang, A.B.; Anderson, J.; Arnold, D.; Goyal, V.; Dunbar, M.; Otim, M.; O’Grady, K.F. The Incidence and Short-term Outcomes of Acute Respiratory Illness with Cough in Children from a Socioeconomically Disadvantaged Urban Community in Australia: A Community-Based Prospective Cohort Study. *Front. Pediatr.* 2017, 5, 228. [CrossRef] [PubMed]
9. O’Grady, K.F.; Grimwood, K.; Toombs, M.; Sloots, T.P.; Otim, M.; Whiteley, D.; Anderson, J.; Rablin, S.; Torzillo, P.J.; Buntain, H.; et al. Effectiveness of a cough management algorithm at the transitional phase from acute to chronic cough in Australian children aged <15 years: Protocol for a randomised controlled trial. *BMJ Open* 2017, 7, e013796. [CrossRef] [PubMed]
10. O’Grady, K.F.; Grimwood, K.; Torzillo, P.J.; Rablin, S.; Lovie-Toon, Y.; Kaus, M.; Arnold, D.; Roberts, J.; Buntain, H.; Adsett, D.; et al. Effectiveness of a chronic cough management algorithm at the transitional stage from acute to chronic cough in children: A multicenter, nested, single-blind, randomised controlled trial. *Lancet Child Adolesc. Health* 2019, 3, 889–898. [CrossRef]
11. Gibson, P.G.; Chang, A.B.; Glasgow, N.J.; Holmes, P.W.; Katelaris, P.; Kemp, A.S.; Landau, L.I.; Mazzone, S.; Newcombe, P.; van Asperen, P.; et al. CICADA: Cough in Children and Adults: Diagnosis and Assessment. Australian cough guidelines summary statement. *Med. J. Aust.* 2010, 192, 265–271. [CrossRef]
12. Chang, A.B.; Oppenheimer, J.J.; Weinberger, M.; Grant, C.C.; Rubin, B.K.; Irwin, R.S.; Panel, C.E.C. Etiologies of Chronic Cough in Pediatric Cohorts: CHEST Guideline and Expert Panel Report. *Chest* 2017, 152, 607–617. [CrossRef] [PubMed]
13. Chang, A.B.; Robertson, C.F.; van Asperen, P.P.; Glasgow, N.J.; Masters, I.B.; Teoh, L.; Mells, C.M.; Landau, L.I.; Marchant, J.M.; Morris, P.S. A cough algorithm for chronic cough in children: A multicenter, randomized controlled study. *Pediatrics* 2013, 131, e1576–e1583. [CrossRef]
14. Asilsoy, S.; Bayram, E.; Agin, H.; Apa, H.; Can, D.; Gulle, S.; Altinoz, S. Evaluation of chronic cough in children. *Chest* 2008, 134, 1122–1128. [CrossRef] [PubMed]
15. Lau, G.T.Y.; Laird, P.; Stevenson, P.G.; Schultz, A. Frequency of protracted bacterial bronchitis and management pre-respiratory referral. *J. Paediatr. Child Health* 2021, online ahead of print. [CrossRef] [PubMed]
16. Gedik, A.H.; Cakir, E.; Torun, E.; Demir, A.D.; Kucukkok, M.; Erenberk, U.; Uzuner, S.; Nursoy, M.; Ozkaya, E.; Aksoy, F.; et al. Evaluation of 563 children with chronic cough accompanied by a new clinical algorithm. *Ital. J. Pediatr.* 2015, 41, 73. [CrossRef]
17. Chang, A.B.; Robertson, C.F.; Van, A.P.P.; Glasgow, N.; Mellis, C.M.; Masters, I.B.; Teoh, L.; Tjhung, I.; Morris, P.S.; Petsky, H.L.; et al. A multi-centre study on chronic cough in children: Burden and etiologies based on a standardized management pathway. *Chest* 2012, 142, 943–950. [CrossRef] [PubMed]

18. Craven, V.; Everard, M.L. Protracted bacterial bronchitis: Reinventing an old disease. *Arch. Dis. Child.* 2012, 98, 72–76. [CrossRef]

19. Au-Yeung, Y.T.; Chang, A.B.; Grimwood, K.; Lovie-Toon, Y.; Kaus, M.; Rablin, S.; Arnold, D.; Roberts, J.; Parfitt, S.; Anderson, J.; et al. Risk Factors for Chronic Cough in Young Children: A Cohort Study. *Front. Pediatr.* 2020, 8, 444. [CrossRef]

20. Wurzel, D.F.; Marchant, J.M.; Yerkovich, S.T.; Upham, J.W.; Mackay, I.M.; Masters, I.B.; Chang, A.B. Prospective characterization of protracted bronchitis in children. *Chest* 2014, 145, 1271–1278. [CrossRef] [PubMed]

21. Chang, A.B.; Upham, J.W.; Masters, I.B.; Redding, G.R.; Gibson, P.G.; Marchant, J.M.; Grimwood, K. Protracted bacterial bronchitis: The last decade and the road ahead. The road ahead. *Pediatr. Pulmonol.* 2016, 51, 225–242. [CrossRef] [PubMed]

22. Yang, C.L.; Simons, E.; Foyt, R.G.; Subbarao, P.; To, T.; Dell, S.D. Misdiagnosis of asthma in schoolchildren. *Pediatr. Pulmonol.* 2017, 52, 293–302. [CrossRef] [PubMed]

23. Korsten, K.; Naaktgeboren, C.A.; Bont, L.; van der Ent, C.K.; de Hoog, M.L.A. Defining asthma in children: How well do parents, doctors and spirometry agree? *ERJ Open Res.* 2020, 6, 00348-2019. [CrossRef]

24. Saglani, S.; Menzie-Gow, A.N. Approaches to Asthma Diagnosis in Children and Adults. *Front. Pediatr.* 2019, 7, 148. [CrossRef] [PubMed]

25. Chang, A.B.; Glomb, W.B. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. *Chest* 2006, 129, 2605–2635. [CrossRef] [PubMed]

26. McFadden, E.R., Jr. Exertional dyspnea and cough as preludes to acute attacks of bronchial asthma. *N. Engl. J. Med.* 1975, 292, 555–559. [CrossRef] [PubMed]

27. Chang, A.B.; Oppenheimer, J.J.; Irwin, R.S.; Panel, C.E.C. Managing Chronic Cough as a Symptom in Children and Management Algorithms: CHEST Guideline and Expert Panel Report. *Chest* 2020, 158, 303–329. [CrossRef] [PubMed]

28. Petsky, H.L.; Acworth, J.P.; Clark, R.; Thearle, D.M.; Masters, I.B.; Chang, A.B. Asthma and protracted bronchitis: Who fares better during an acute respiratory infection? *J. Paediatr. Child Health* 2009, 45, 42–47. [CrossRef] [PubMed]

29. Baines, K.J.; Upham, J.W.; Yerkovich, S.T.; Chang, A.B.; Marchant, J.M.; Carroll, M.; Simpson, J.L.; Gibson, P.G. Mediators of neutrophil function in children with protracted bacterial bronchitis. *Chest* 2014, 146, 1013–1020. [CrossRef]

30. Hodge, S.; Upham, J.W.; Pizzutto, S.; Petsky, H.L.; Yerkovich, S.; Baines, K.J.; Gibson, P.; Simpson, J.L.; Buntain, H.; Chen, A.C.H.; et al. Is Alveolar Macrophage Phagocytic Dysfunction in Children With Protracted Bacterial Bronchitis a Forerunner to Bronchiectasis? *Chest* 2016, 149, 508–515. [CrossRef] [PubMed]

31. Rudan, I.; O’Brien, K.L.; Nair, H.; Liu, L.; Theodoratou, E.; Qazi, S.; Luksic, I.; Fischer Walker, C.L.; Black, R.E.; Campbell, H.; et al. Epidemiology and etiology of childhood pneumonia in 2010: Estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. *J. Glob. Health* 2013, 3, 010401. [PubMed]

32. Douros, K.; Everard, M.L. Time to Say Goodbye to Bronchiolitis, Viral Wheeze, Reactive Airways Disease, Wheeze Bronchitis and All That. *Front. Pediatr.* 2020, 8, 218. [CrossRef] [PubMed]

33. Escribano Montaner, A.; Garcia de Lomas, J.; Villa Asensi, J.R.; Asensio de la Cruz, O.; de la Serna Blazquez, O.; Santiago Burruchaga, M.; Mondejar Lopez, P.; Torrent Vernetta, A.; Feng, Y.; Van Dyke, M.K.; et al. Bacteria from bronchoalveolar lavage fluid from children with suspected chronic lower respiratory tract infection: Results from a multi-center, cross-sectional study in Spain. *Eur. J. Pediatr.* 2018, 177, 181–192. [CrossRef]

34. Hare, K.M.; Chang, A.B.; Smith-Vaughan, H.C.; Bauert, P.A.; Spain, B.; Beissbarth, J.; Grimwood, K. Do combined upper airway cultures identify lower airway infections in children with chronic cough? *Pediatr. Pulmonol.* 2019, 54, 907–913. [CrossRef] [PubMed]

35. Murphy, T.F.; Parameswaran, G.I. Moraxella catarrhalis, a human respiratory tract pathogen. *Clin. Infect. Dis.* 2009, 49, 124–131. [CrossRef]

36. Ngu, C.C.; Massa, H.M.; Thornton, R.B.; Cripps, A.W. Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic Review. *PLoS ONE* 2016, 11, e0150949. [CrossRef]

37. Murphy, T.F.; Brauer, A.L.; Grant, B.J.; Sethi, S. Moraxella catarrhalis in chronic obstructive pulmonary disease: Burden of disease and immune response. *Am. J. Respir. Crit. Care Med.* 2005, 172, 195–199. [CrossRef] [PubMed]

38. Welp, A.L.; Bomberger, J.M. Bacterial Community Interactions During Chronic Respiratory Disease. *Front. Cell Infect. Microbiol.* 2020, 10, 213. [CrossRef]

39. Gallucci, M.; Pedretti, M.; Giannetti, A.; di Palmo, E.; Bertelli, L.; Pession, A.; Ricci, G. When the Cough Does Not Improve: A Review on Protracted Bacterial Bronchitis in Children. *Front. Pediatr.* 2020, 8, 433. [CrossRef]

40. O’Grady, K.F.; Grimwood, K.; Sloots, T.P.; Whiteley, D.M.; Acworth, J.P.; Phillips, N.; Marchant, J.; Goyal, V.; Chang, A.B. Upper airway viruses and bacteria and clinical outcomes in children with cough. *Pediatr. Pulmonol.* 2017, 52, 373–381. [CrossRef] [PubMed]

41. Latzin, P.; Fuchs, O. Asthma diagnosis in children: More evidence needed. *Lancet Child Adolesc. Health* 2017, 1, 83–85. [CrossRef]

42. Marchant, J.M.; Newcombe, P.A.; Juniper, E.F.; Sheffield, J.K.; Statthís, S.L.; Chang, A.B. What is the burden of chronic cough for families? *Chest* 2008, 134, 303–309. [CrossRef] [PubMed]
43. Lovie-Toon, Y.G.; Chang, A.B.; Newcombe, P.A.; Vagenas, D.; Anderson-James, S.; Drescher, B.J.; Otim, M.E.; O’Grady, K.F. Longitudinal study of quality of life among children with acute respiratory infection and cough. *Qual. Life Res.* **2018**, *27*, 891–903. [CrossRef] [PubMed]

44. Prime, S.J.; Carter, H.E.; McPhail, S.M.; Petsky, H.L.; Chang, A.B.; Graves, N.; Marchant, J.M. Chronic wet cough in Australian children: Societal costs and quality of life. *Pediatr. Pulmonol.* **2021**, *56*, 2707–2716. [CrossRef] [PubMed]

45. Ruffles, T.J.C.; Marchant, J.M.; Masters, I.B.; Yerkovich, S.T.; Wurzel, D.F.; Gibson, P.G.; Busch, G.; Baines, K.J.; Simpson, J.L.; Smith-Vaughan, H.C.; et al. Outcomes of protracted bacterial bronchitis in children: A 5-year prospective cohort study. *Respirology* **2021**, *26*, 241–248. [CrossRef]